$VIVS

VivoSim Labs, INC.

CIK:0001497253|SEC Filings

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Revenues
Total Revenues	$ 18	$ 37
Research and development expenses	1,132	1,001
Selling, general and administrative expenses	1,645	1,951
Total costs and expenses	2,777	2,952
Loss from Operations	(2,759)	(2,915)
Other Income (Expense)
Gain on change in fair value of common stock warrant liabilities	1,400	0
Interest income	28	76
Interest expense	(4)	(4)
Total Other Income	1,424	72
Income Tax Expense	(3)	0
Net Loss	(1,338)	(2,843)
Comprehensive Loss	$ (1,338)	$ (2,843)
Net loss per common share basic	$ (0.25)	$ (1.14)
Net loss per common share diluted	$ (0.25)	$ (1.14)
Weighted average shares used in computing net loss per common share basic	5,239,462	2,503,697
Weighted average shares used in computing net loss per common share diluted	5,239,462	2,503,697
Royalty Revenue [Member]
Revenues
Total Revenues	$ 18	$ 37

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows from Operating Activities
Net loss	$ (1,338)	$ (2,843)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on change in fair value of common stock warrant liabilities	(1,400)	0
Interest accretion on escrow receivable	(2)	(4)
Depreciation and amortization	40	61
Stock-based compensation	91	78
Non-cash lease expense	120	112
Increase (decrease) in cash resulting from changes in:
Accounts receivable	3	(2)
Prepaid expenses and other assets	47	248
Accounts payable	(400)	(971)
Accrued expenses	(243)	(499)
Operating lease liabiliy	(131)	(120)
Net cash used in operating activities	(3,213)	(3,940)
Cash Flows from Investing Activities
Purchases of fixed assets	(23)	0
Net cash used in investing activities	(23)	0
Cash Flows from Financing Activities
Proceeds from issuance of common stock, net	0	1,811
Repayment of insurance premium financing liability	(118)	(128)
Net cash (used in) provided by financing activities	(118)	1,683
Net decrease in cash, cash equivalents, and restricted cash	(3,354)	(2,257)
Cash, cash equivalents, and restricted cash at beginning of period	5,167	11,455
Cash, cash equivalents, and restricted cash at end of period	1,813	9,198
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	1,670	9,055
Restricted cash	143	143
Cash, cash equivalents, and restricted cash at end of period	1,813	9,198
Supplemental Disclosure of Cash Flow Information:
Income taxes paid	3	0
Interest paid	$ 4	$ 4

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Mar. 31, 2026
Current Assets
Cash and cash equivalents	$ 1,670,000	$ 5,024,000
Accounts receivable	29,000	32,000
Escrow receivable	1,016,000	1,014,000
Prepaid expenses and other current assets	511,000	557,000
Total current assets	3,226,000	6,627,000
Fixed assets, net	189,000	206,000
Restricted cash	143,000	143,000
Operating lease right-of-use assets	287,000	407,000
Prepaid expenses and other assets, net	2,000	3,000
Total assets	3,847,000	7,386,000
Current Liabilities
Accounts payable	621,000	1,021,000
Accrued expenses	738,000	981,000
Insurance premium financing liability	0	118,000
Liability to be settled in equity	218,000	218,000
Operating lease liability, current portion	316,000	447,000
Total current liabilities	1,893,000	2,785,000
Common stock warrant liabilities	4,300,000	5,700,000
Total liabilities	6,193,000	8,485,000
Commitments and Contingencies (Note 6)
Stockholders' Deficit
Common stock, $0.001 par value; 200,000,000 shares authorized, 3,194,295 and 2,894,519 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively	3,000	3,000
Additional paid-in capital	354,989,000	354,898,000
Accumulated deficit	(357,338,000)	(356,000,000)
Total stockholders' deficit	(2,346,000)	(1,099,000)
Total Liabilities and Stockholders' Deficit	$ 3,847,000	$ 7,386,000